As of November 6, 2026, Olema Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: OLMA). The largest holder reporting an active stake on Schedule 13D is Biotechnology Value Fund LP, at 9.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (13.8%), Janus Henderson (8.2%), Bain Capital Life Sciences Opportunities IV, L.P. (8.15%) (Schedule 13D/A, October 16, 2026).
Is this your company?
About to sign with, pay or invest in Olema Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Olema Pharmaceuticals, Inc. a real, registered company?
- Olema Pharmaceuticals, Inc. files with the SEC under CIK 1750284 (its SEC filings).
- Its shares are listed under the ticker OLMA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Olema Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Gorjan Hrustanovic (Form 8-K filed 2026-10-15). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Biotechnology Value Fund LP (filed 2026-10-16).
Who are Olema Pharmaceuticals, Inc.'s owners and officers?
Olema Pharmaceuticals, Inc.: incorporated in Delaware; business address in San Francisco, California; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-10-16).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-12-12)
- : Executive Officer (Form D, 2024-12-12)
- : Executive Officer (Form D, 2024-12-12)
- : Executive Officer (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
- : Director (Form D, 2024-12-12)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-10-16 | Biotechnology Value Fund L P | 9.8% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 13.8% |
| Schedule 13G/A, 2026-07-29 | Blackrock, Inc. | 7.1% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 8.2% |
| Schedule 13G/A, 2026-05-15 | Bain Capital Life Sciences Opportunities Iv, L.P. | 8.15% |
| Schedule 13G, 2026-03-20 | Raymond Debbane | 5.1% |
| Schedule 13G/A, 2026-03-06 | Fmr LLC | 12.5% |
| Schedule 13G/A, 2026-02-17 | Bain Capital Life Sciences Opportunities Iv, L.P. | 9.99% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 8.4% |
| Schedule 13G/A, 2026-02-13 | Deep Track Capital, LP | 0% |
| Schedule 13G, 2026-02-05 | Fmr LLC | 6.3% |
| Schedule 13G, 2025-11-14 | Janus Henderson Group PLC | 5.2% |
Questions about who owns Olema Pharmaceuticals, Inc.
Who owns Olema Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Olema Pharmaceuticals, Inc.: Fmr LLC (13.8%, Schedule 13G/A, filed 2026-08-06), Biotechnology Value Fund L P (9.8%, Schedule 13D/A, filed 2026-10-16), Janus Henderson Group PLC (8.2%, Schedule 13G/A, filed 2026-05-15), Bain Capital Life Sciences Opportunities Iv, L.P. (8.15%, Schedule 13G/A, filed 2026-05-15) and Blackrock, Inc. (7.1%, Schedule 13G/A, filed 2026-07-29); 1 more is listed above.
Who are the largest shareholders of Olema Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Olema Pharmaceuticals, Inc. on this page are Fmr LLC (13.8%), Biotechnology Value Fund L P (9.8%) and Janus Henderson Group PLC (8.2%).
When did Fmr LLC buy into Olema Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-02-05, reporting 6.3%; its latest, Schedule 13G/A filed 2026-08-06, reports 13.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Olema Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Olema Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Olema Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-15 | Gorjan Hrustanovic | departed | 2026-10-14 | |
| Form 8-K, 2026-04-29 | Prakash Raman | Director | appointed | 2026-04-28 |
Which insiders own Olema Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Bain Capital Life Sciences Fund IV, L.P., a 10% owner: 4,300,000 shares (4.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-13).
- Bain Capital Life Sciences Opportunities IV GP, LLC, a 10% owner: 4,300,000 shares (4.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-13).
- Bain Capital Life Sciences Investors, LLC, a 10% owner: 4,300,000 shares (4.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-13).
- Bain Capital Life Sciences Opportunities IV, L.P., a 10% owner: 4,300,000 shares (4.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-13).
- Bain Capital Life Sciences IV General Partner, LLC, a 10% owner: 4,300,000 shares (4.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-13).
Shares outstanding: 87,497,607 as of 2026-08-06, from the company's latest SEC cover page.
How much has Olema Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-12-12 | $250M | $250M |
| Form D, 2023-09-14 | $130M | $130M |
Keep reading
More on Olema Pharmaceuticals, Inc. and the records around it.
Olema Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Aug 2026
Companies that share a holder
- Bain Capital Life Sciences Opportunities IV, L.P. also filed stake reports on 1 other company: ADC Therapeutics SA (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026), Stoke Therapeutics, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/olema-pharmaceuticals